Showing results (171-180 of 481) with videos related to
Sort By:
Pageof 49
Clinical Chemistry|July 9, 2025
A Modified Sampson-NIH Equation with Improved Accuracy for Estimating Low Levels of Low-Density Lipoprotein-CholesterolMaureen Sampson, Rafael Zubiran, Anna Wolska, et al.Journal of the American College of Cardiology|November 14, 2009
The relative efficacy and safety of clopidogrel in women and men a sex-specific collaborative meta-analysisJeffrey S Berger, Deepak L Bhatt, Christopher P Cannon, et al.Journal of the American College of Cardiology|January 29, 2008
Polymorphism in KIF6 gene and benefit from statins after acute coronary syndromes: results from the PROVE IT-TIMI 22 studyOlga A Iakoubova, Marc S Sabatine, Charles M Rowland, et al.Circulation|November 21, 2013
Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) randomized trialMichael J Koren, Robert P Giugliano, Frederick J Raal, et al.Circulation. Cardiovascular Interventions|June 14, 2018
Activated Clotting Time to Guide Heparin Dosing in Non-ST-Segment-Elevation Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention and Treated With IIb/IIIa Inhibitors: Impact on Ischemic and Bleeding Outcomes: Insights From the TAO TrialJean-Guillaume Dillinger, Gregory Ducrocq, Yedid Elbez, et al.The American Journal of Cardiology|August 30, 2008
Outcomes of patients with acute coronary syndrome and previous coronary artery bypass grafting (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy [PROVE IT-TIMI 22] and the Aggrastat to Zocor [A to Z] trials)Emmanouil S Brilakis, James A de Lemos, Christopher P Cannon, et al.JAMA Cardiology|November 9, 2017
Clinical Efficacy and Safety of Evolocumab in High-Risk Patients Receiving a Statin: Secondary Analysis of Patients With Low LDL Cholesterol Levels and in Those Already Receiving a Maximal-Potency Statin in a Randomized Clinical TrialRobert P Giugliano, Anthony Keech, Sabina A Murphy, et al.The American Journal of Cardiology|December 9, 2022
Clinical Significance of Culprit Vessel Occlusion in Patients With Non-ST-Elevation Myocardial Infarction Who Underwent Percutaneous Coronary InterventionBatric Popovic, Gregory Ducrocq, Yedid Elbez, et al.Clinical Cardiology|February 17, 2017
Design and rationale of the EBBINGHAUS trial: A phase 3, double-blind, placebo-controlled, multicenter study to assess the effect of evolocumab on cognitive function in patients with clinically evident cardiovascular disease and receiving statin background lipid-lowering therapy-A cognitive study of patients enrolled in the FOURIER trialRobert P Giugliano, Francois Mach, Kenton Zavitz, et al.Journal of the American College of Cardiology|April 15, 2014
Fibroblast growth factor-23, cardiovascular prognosis, and benefit of angiotensin-converting enzyme inhibition in stable ischemic heart diseaseJacob A Udell, David A Morrow, Petr Jarolim, et al.Pageof 49